ClinicalTrials.Veeva

Menu

Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS)

M

Mingdong Hu

Status

Unknown

Conditions

Respiratory Distress Syndrome, Adult

Study type

Observational

Funder types

Other

Identifiers

NCT03236272
TMMUHMD76

Details and patient eligibility

About

The aim of the investigators 'study is to investigate the relationship between the biomarkers (e.g. protein markers, genetic polymorphisms and epigenetic markers) and the onset of ARDS. In this study, the participants were divided into case group (with ARDS) and control group (without ARDS), based on a nested case-control study method. During the diagnosis and treatment, the clinical data of subjects are collected at the given time point. And the clinical data are extracted from plasma, blood and bronchoalveolar lavage fluid of participants. These data will be analyzed based on statistical methods. In the end ,the investigators can build a multi index early warning model based on the biomarkers,which is meaningful for the early diagnosis of the patient with high-risk for ARDS and provide evidence for the early treatment.

Full description

The investigators studied patients at high risk of acute respiratory distress syndrome (ARDS) and ARDS patients. The patients with ARDS were the case group, and the patients without ARDS were the control group .Sample size estimate :set alpha =0.05,1- beta =0.8, estimated cases exposure rate was 50%, the control group estimated exposure rate was 35%, according to a case-control study of sample size estimation formula for sample size calculation, and considering the loss rate is 10%, the sample size for each group of 188 cases, two groups of 376 cases. The plasma, blood and bronchoalveolar lavage fluid will be collected during the diagnosis and treatment,to study biomarkers related to the onset of ARDS, such as protein markers,genetic polymorphisms and epigenetic markers.The observation data of two groups will be compared .The clinical data are collected at the given time point. The stepwise regression (forward-conditional) will be used for establishing a multivariate unconditional logistic regression model that will contribute to screened the main risk factor and protective factors that affect the ARDS. And these factor will help to established the early warning model and the risk function of ARDS in high-risk patients, which will contribute to predict the risk of ARDS in high-risk patients.All information about the subjects is strictly confidential, and the results of the study may be reported at medical conferences and published in scientific journals, but any individual who can identify subjects will not be able to use.

Enrollment

376 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. High-risk cases ARDS inclusion criteria:

    • Acute onset (within 1 weeks)
    • Pneumonia,Aspiration,Sepsis,Acute pancreatitis,Shock,High-risk trauma and other unexpected severe diseases.
    • Pao2/Fio2>300mmhg
    • 18 to 80 years old
    • The subjects agreed to sign the informed consent
  2. ARDS Inclusion criteria:

    • Acute onset (within 1 weeks)
    • Pneumonia,Aspiration,Sepsis,Acute pancreatitis,Shock,High-risk trauma and other unexpected severe diseases.
    • Pao2/Fio2<300mmhg
    • 18 to 80 years old
    • The subjects agreed to sign the informed consent

Exclusion criteria

  • patients who developed ARDS before initial evaluation or blood collection
  • patients who were rehospitalized
  • the hospital stay was shorter than 7 days, and it was unfeasible to determine the clinical outcome
  • patients who died within 6h of admission
  • patients had a history of chronic interstitial lung disease
  • patients with an age of less than 18 years old
  • Patients were immunodeficiency (eg, eukaemia) or treated with cytotoxic drugs
  • patients who were pregnant
  • patients who were refused to join.

Trial design

376 participants in 2 patient groups

case group
Description:
patients with ARDS
control group
Description:
patients Without ARDS

Trial contacts and locations

1

Loading...

Central trial contact

Wang dan; Hu Mingdong, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems